Passa al contenuto
Merck
  • Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration.

Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration.

Journal of psychopharmacology (Oxford, England) (2014-04-05)
Nicoletta Croce, Aleksander A Mathé, Francesca Gelfo, Carlo Caltagirone, Sergio Bernardini, Francesco Angelucci
ABSTRACT

One of the common effects of lithium (Li) and valproic acid (VPA) is their ability to protect against excitotoxic insults. Neurodegenerative and neuropsychiatric diseases may be also associated with altered trophic support of brain-derived neurotrophic factor (BDNF), the most widely distributed neurotrophin in the central nervous system. However, despite these evidences, the effect of Li-VPA combination on BDNF after excitoxic insult has been inadequately investigated. We address this issue by exposing a human neuroblastoma cell line (SH-SY5Y) to neurotoxic concentration of L-glutamate and exploring whether the neuroprotective action of Li-VPA on these cells is associated with changes in BDNF protein and mRNA levels. The results showed that pre-incubation of Li-VPA abolished the toxic effect of glutamate on SH-SY5Y cell survival and this neuroprotective effect was associated with increased synthesis and mRNA expression of BDNF after 24 and 48 h of incubation. In conclusion, this study demonstrates that the neuroprotective effects of Li-VPA against glutamate-induced neurotoxicity in SH-SY5Y neuroblastoma cells is associated with increased synthesis and mRNA expression of BDNF. These data further support the idea that these two drugs can be used for prevention and/or treatment of glutamate-related neurodegenerative disorders.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Acido retinoico, ≥98% (HPLC), powder
Sigma-Aldrich
L-glutammina, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Lithium carbonate, ACS reagent, ≥99.0%
Sigma-Aldrich
Acido L-glutammico, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
L-glutammina, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Valproic acid sodium salt, 98%
SAFC
L-glutammina
Sigma-Aldrich
Acido L-glutammico, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-100.5%
Sigma-Aldrich
Lithium carbonate, puriss. p.a., ACS reagent, ≥99.0% (T)
Sigma-Aldrich
Acido L-glutammico, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-glutammina, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Lithium carbonate, 99.999% trace metals basis
Supelco
Acido L-glutammico, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-glutammina, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-glutammina
Sigma-Aldrich
Lithium carbonate, 99.997% trace metals basis
Sigma-Aldrich
Acido L-glutammico, FCC
Supelco
L-glutammina, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lithium-7Li2 carbonate, ≥99 atom % 7Li, 99% (CP)
Supelco
Acido L-glutammico, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-glutammina, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland